Karl Strecker

Summary

Affiliation: University of Leipzig
Country: Germany

Publications

  1. ncbi request reprint Parkinson's disease: emerging pharmacotherapy
    Karl Strecker
    Department of Neurology, University of Leipzig, Movement Disorders Group, Liebigstrasse 22 a, 04103 Leipzig, Germany
    Expert Opin Emerg Drugs 13:573-91. 2008
  2. doi request reprint Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up
    Swen Hesse
    Dept of Nuclear Medicine, University of Leipzig, Stephanstrasse 11, 04103 Leipzig, Germany
    J Neurol 255:1059-66. 2008
  3. doi request reprint Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter
    Karl Strecker
    Department of Neurology, University of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany
    J Neurol 258:19-26. 2011
  4. doi request reprint The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice
    Karl Strecker
    NRZ, Neurological Rehabilitation Center, University of Leipzig, Muldentalweg 1, 04828 Bennewitz, Germany
    J Neural Transm 119:1351-9. 2012
  5. doi request reprint Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Martin Wolz
    Department of Neurology, Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany
    J Neural Transm 117:1279-86. 2010
  6. doi request reprint Increase of frequency in deep brain stimulation relieves apraxia of eyelid opening in patients with Parkinson's disease: case report
    Karl Strecker
    Department of Neurology, University of Leipzig, Leipzig, Germany
    Neurosurgery 63:E1204; discussion E1204. 2008
  7. doi request reprint Monoamine transporter availability in Parkinson's disease patients with or without depression
    Swen Hesse
    Department of Nuclear Medicine, University of Leipzig, Stephanstrasse 11, 04103 Leipzig, Germany
    Eur J Nucl Med Mol Imaging 36:428-35. 2009

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Parkinson's disease: emerging pharmacotherapy
    Karl Strecker
    Department of Neurology, University of Leipzig, Movement Disorders Group, Liebigstrasse 22 a, 04103 Leipzig, Germany
    Expert Opin Emerg Drugs 13:573-91. 2008
    ..Here, we describe current therapies and possible future developments that we hope will contribute to sustaining quality of life in patients suffering from Parkinson's disease for many years...
  2. doi request reprint Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up
    Swen Hesse
    Dept of Nuclear Medicine, University of Leipzig, Stephanstrasse 11, 04103 Leipzig, Germany
    J Neurol 255:1059-66. 2008
    ..These data show that clinical improvement and reduction of dopaminergic drugs in patients with advanced PD undergoing bilateral STN-DBS are paralleled by stable DAT and recovery of striatal D2R availability 12 months after surgery...
  3. doi request reprint Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter
    Karl Strecker
    Department of Neurology, University of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany
    J Neurol 258:19-26. 2011
    ..No alteration of SERT binding in our patients suggests that the serotonergic system is remarkably preserved in early PD. Correlation with DAT might point to a compensatory regulation of the serotonergic system in early stages of PD...
  4. doi request reprint The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice
    Karl Strecker
    NRZ, Neurological Rehabilitation Center, University of Leipzig, Muldentalweg 1, 04828 Bennewitz, Germany
    J Neural Transm 119:1351-9. 2012
    ..04). Flibanserin showed promising antidyskinetic effects in a model of drug-induced dyskinesia. Our data underline the possible benefit of 5-HT1A agonists in drug-induced dyskinesia...
  5. doi request reprint Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Martin Wolz
    Department of Neurology, Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany
    J Neural Transm 117:1279-86. 2010
    ..LEV was well tolerated in doses up to 2,000 mg/day. Further large controlled studies are warranted to evaluate the impact of LEV on LID in PD patients...
  6. doi request reprint Increase of frequency in deep brain stimulation relieves apraxia of eyelid opening in patients with Parkinson's disease: case report
    Karl Strecker
    Department of Neurology, University of Leipzig, Leipzig, Germany
    Neurosurgery 63:E1204; discussion E1204. 2008
    ..However, approximately 5% of patients might develop apraxia of eyelid opening after DBS of the subthalamic nucleus. We provide data on a new noninvasive treatment approach to this adverse event...
  7. doi request reprint Monoamine transporter availability in Parkinson's disease patients with or without depression
    Swen Hesse
    Department of Nuclear Medicine, University of Leipzig, Stephanstrasse 11, 04103 Leipzig, Germany
    Eur J Nucl Med Mol Imaging 36:428-35. 2009
    ..Therefore, we studied PD patients with depression (PD+D) and without depression (PD-D) using high-resolution single-photon emission computed tomography (SPECT) and the monoamine transporter marker [(123)I]FP-CIT...